Minireviews
Copyright ©The Author(s) 2019.
World J Gastroenterol. Feb 21, 2019; 25(7): 789-807
Published online Feb 21, 2019. doi: 10.3748/wjg.v25.i7.789
Table 5 Results of the CERESTIAL trial[45]
Cabozantinib (n = 470)Placebo (n = 237)HR, P-value
OS (M, 95%CI)10.2 (9.1-12.0)8.0 (6.8-9.4)HR 0.76 (95%CI 0.63-0.92) P = 0.0049
PFS (M, 95%CI)5.2 (4.0-5.5)1.9 (1.9-1.9)HR 0.44 (95%CI 0.36-0.52) P < 0.0001
Objective response (investigator assessed, RECIST 1.1)
CR (%)00
PR (%)40.4
SD (%)6033
PD (%)2155
NE (%)1511
ORR (%, 95CI)4 (2.3-6.0)0.4 (0.0-2.3)P = 0.0086
DCR (%)6433.4